Vaborem 1 g/1 g powder for concentrate for solution for infusion

DRUG3 trials

Sponsors

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla, Menarini Ricerche S.p.A., Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico

Conditions

Bacteriemia producida por P. aeruginosa.Patients colonized with CPE undergoing liver transplantation (LT)Suspected or confirmed Gram negative infections

Phase 2

An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population with suspected or confirmed Gram negative infections, including but not restricted to Complicated Urinary Tract Infections.

RecruitingCTIS2024-514656-32-00

Menarini Ricerche S.p.A.Suspected or confirmed Gram negative infections

Start: 2025-01-23Target: 44Updated: 2025-09-12

Phase 3

Targeted versus standard peri-operative prophylaxis in patients colonized with carbapenemase-producing Enterobacterales undergoing liver transplantation: a stepped-wedge cluster randomization trial

Not yet recruitingCTIS2025-523453-34-00

Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoPatients colonized with CPE undergoing liver transplantation (LT)

Target: 168Updated: 2026-08-31

Phase 4

Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis.

Not yet recruitingCTIS2023-508441-41-00

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De SevillaBacteriemia producida por P. aeruginosa.

Target: 306Updated: 2025-07-25